Verified Nov 2026
Batteries & E-Mobility
·
Seal Beach, California
·
Since 1992
Dendreon is a biopharmaceutical company founded in 1992 and headquartered in Seal Beach, California, with an employee band of 500 to 1,000. It is publicly listed under the ticker DNDN. The company develops autologous cell immunotherapies in which a patient's own immune cells are processed and reinfused to target tumor cells, and it also offers contract manufacturing services for cell therapies. Its serves oncology and urology markets, and its marketed product PROVENGE (sipuleucel-T) is an FDA-approved treatment for prostate cancer.
Dendreon at a glance
Revenue
312M
Employees
500-1,000
Founded
1992
Headquarters
Seal Beach, California
Ownership
Publicly traded (NASDAQ: DNDN)
Import activity
4
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
4
Named foreign suppliers
1
Top origins
Italy
Shared foreign counterparties do not establish that these companies buy from Dendreon.
What this tells a buyer
Recent public reporting describes Dendreon hiring regional business directors and key account managers in April 2026 to support continued U.S. access to PROVENGE.
The company's stated capabilities include end-to-end contract manufacturing for cell therapies, logistics support, and regulatory guidance, alongside its in-house immunotherapy development.
Dendreon is publicly traded, and in March 2026 it was reported to have lobbied the Department of Veterans Affairs on prostate cancer treatment pathways.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Dendreon is a biopharmaceutical company founded in 1992 and headquartered in Seal Beach, California, with an employee band of 500 to 1,000. It is publicly listed under the ticker DNDN. The company develops autologous cell immunotherapies in which a patient's own immune cells are processed and reinfused to target tumor cells, and it also offers contract manufacturing services for cell therapies. Its serves oncology and urology markets, and its marketed product PROVENGE (sipuleucel-T) is an FDA-approved treatment for prostate cancer.
At a glance
Attribute | Detail |
|---|---|
Founded | 1992 |
Headquarters | Seal Beach, California |
Employees | 500-1,000 |
Revenue | 312M |
Ownership | Publicly traded (NASDAQ: DNDN) |
Primary capability | Batteries & E-Mobility |
What Dendreon makes
The company's stated capabilities include end-to-end contract manufacturing for cell therapies, logistics support, and regulatory guidance, alongside its in-house immunotherapy development.
Trade and customs footprint
Recent public reporting describes Dendreon hiring regional business directors and key account managers in April 2026 to support continued U.S. access to PROVENGE. US customs bill-of-lading records list 4 inbound shipments across 1 foreign suppliers, with top origins including Italy.
Latest developments
2026-10-16 — Executive Director, Business Development & Corporate Strategy at Dendreon (greenhouse.io)
2026-08-31 — I’m excited to announce I’ll be starting a new role at Dendreon Pharmaceuticals this week as Sr. Program Manager, CMS. Looking forward to this new chapter in my career, managing contract manufacturing … | George Todorov (linkedin.com)
2026-04-29 — Dendreon is hiring Regional Business Directors and Key Account Managers to support continued access to PROVENGE® (sipuleucel T) across key U.S. markets. | Dendreon (linkedin.com)
2026-04-09 — Georgia Life Sciences was pleased to join member company Dendreon in welcoming Congresswoman Lucy McBath for a tour of their Union City facility. | Georgia Life Sciences (linkedin.com)
2026-03-03 — Dendreon Lobbies VA on Prostate Cancer Pathways | Legis1 (legis1.com)
2026-02-23 — Excited to have Jason and his talent joining our team at Dendreon!! | Scott Hutson (linkedin.com)
Facilities
Dendreon is headquartered in Seal Beach, California. Public sources also reference these locations:
Seal Beach, California — greenhouse.io
Seal Beach, CA — ca.gov
Company details
Dendreon is publicly traded, and in March 2026 it was reported to have lobbied the Department of Veterans Affairs on prostate cancer treatment pathways. Dendreon was founded in 1992, has an estimated 500-1,000 employees, and is headquartered in Seal Beach, California.
Frequently asked questions
What does Dendreon make?
Dendreon is a biopharmaceutical company founded in 1992 and headquartered in Seal Beach, California, with an employee band of 500 to 1,000. It is publicly listed under the ticker DNDN. The company develops autologous cell immunotherapies in which a patient's own immune cells are processed and reinfused to target tumor cells, and it also offers contract manufacturing services for cell therapies. Its serves oncology and urology markets, and its marketed product PROVENGE (sipuleucel-T) is an FDA-approved treatment for prostate cancer.
Where is Dendreon headquartered?
Dendreon is headquartered in Seal Beach, California (1700 Saturn Way, Seal Beach, California, 90740-5618).
When was Dendreon founded?
Dendreon was founded in 1992.
How big is Dendreon?
Dendreon has an estimated 500-1,000 employees, with revenue in the 312M range.
Is Dendreon publicly traded?
Publicly traded (NASDAQ: DNDN). Public financial figures are drawn from its filings.
Does Dendreon import from overseas suppliers?
US customs bill-of-lading records show 4 inbound shipments for Dendreon, with top origins including Italy.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.